| Summary: |
Tenosynovial Giant Cell Tumor (TGCT) is a rare but locally aggressive neoplasm affecting synovial joints, tendon sheaths, and bursae, leading to chronic pain, joint dysfunction, and high recurrence rates. Despite its benign classification, TGCT often requires surgical intervention, posing significant risks of morbidity and functional impairment. Targeted therapies such as pexidartinib offer an alternative, but their use is limited by severe side effects and incomplete responses, underscoring the urgent need for novel treatment strategies. A major obstacle in TGCT research is the lack of physiologically relevant preclinical models that recapitulate tumor-stroma interactions and mechanotransduction cues, which drive disease progression and therapy resistance. Current in vitro models, primarily based on 2D cultures, fail to capture the 3D architecture, extracellular matrix (ECM) remodeling, and mechanical forces that influence tumor behavior in vivo. While animal models provide some insights, they do not fully reflect human pathophysiology and present ethical and translational limitations. Consequently, there is an increasing demand for advanced 3D tumor models that more accurately recreate the TGCT microenvironment, improving therapeutic testing and mechanistic studies.
Recent advancements in 3D cancer modeling-including tumor spheroids, organoids, and bioprinted constructs-offer improvements over conventional systems, yet significant gaps remain. While spheroids self-assemble into 3D structures and mimic solid tumor architecture, they lack ECM complexity, limiting their relevance for ECM-dependent cancers like TGCT. Patient-derived organoids retain genetic and phenotypic characteristics, making them valuable for personalized medicine, but fail to fully recapitulate TGCT's macrophage-driven inflammation and ECM remodeling. Bioprinted tumor constructs provide greater control over spatial organization, ECM composition, and stiffn  |
Summary
Tenosynovial Giant Cell Tumor (TGCT) is a rare but locally aggressive neoplasm affecting synovial joints, tendon sheaths, and bursae, leading to chronic pain, joint dysfunction, and high recurrence rates. Despite its benign classification, TGCT often requires surgical intervention, posing significant risks of morbidity and functional impairment. Targeted therapies such as pexidartinib offer an alternative, but their use is limited by severe side effects and incomplete responses, underscoring the urgent need for novel treatment strategies. A major obstacle in TGCT research is the lack of physiologically relevant preclinical models that recapitulate tumor-stroma interactions and mechanotransduction cues, which drive disease progression and therapy resistance. Current in vitro models, primarily based on 2D cultures, fail to capture the 3D architecture, extracellular matrix (ECM) remodeling, and mechanical forces that influence tumor behavior in vivo. While animal models provide some insights, they do not fully reflect human pathophysiology and present ethical and translational limitations. Consequently, there is an increasing demand for advanced 3D tumor models that more accurately recreate the TGCT microenvironment, improving therapeutic testing and mechanistic studies.
Recent advancements in 3D cancer modeling-including tumor spheroids, organoids, and bioprinted constructs-offer improvements over conventional systems, yet significant gaps remain. While spheroids self-assemble into 3D structures and mimic solid tumor architecture, they lack ECM complexity, limiting their relevance for ECM-dependent cancers like TGCT. Patient-derived organoids retain genetic and phenotypic characteristics, making them valuable for personalized medicine, but fail to fully recapitulate TGCT's macrophage-driven inflammation and ECM remodeling. Bioprinted tumor constructs provide greater control over spatial organization, ECM composition, and stiffness gradients, making them promising for TGCT research. However, existing models lack dynamic control over ECM stiffness and mechanotransduction cues, which are key regulators of tumor progression and therapy response.
MagTumor introduces a groundbreaking approach by integrating magnetic actuation into 3D TGCT models, an innovation that has not yet been explored in this context. TGCT is a highly dynamic disease, with progression, invasiveness, and tumor-stroma interactions evolving over time. By leveraging magnetically responsive systems, we aim to create a tunable, physiologically relevant 3D tumor platform that allows for: i) Precision tumor modeling through magnetic assembly: Using magnetically assisted bioprinting and nanoparticle-based actuation, we will precisely control ECM stiffness, spatial organization, and cellular interactions within the tumor microenvironment. Unlike static models, our system enables real-time modulation of mechanical properties, mimicking the evolving nature of TGCT. ii) Mechanotransduction-driven insights: ECM remodeling and mechanical forces are major regulators of tumor behavior, yet current models fail to capture these critical elements. Our system will enable the study of tumor mechanotransduction pathways, particularly Hippo-YAP/TAZ signaling, providing insights into TGCT invasiveness and therapy resistance. iii) A human-relevant alternative to animal models: By providing a more accurate in vitro representation of TGCT, our model will serve as a translationally relevant alternative to animal studies, reducing reliance on in vivo models while improving predictive power for clinical outcomes. This aligns with global efforts to reduce animal testing and enhance drug discovery pipelines. iv) Enhanced therapeutic testing and drug screening: Our magnetically assembled tumor constructs will serve as high-throughput drug screening platforms, allowing for precise testing of pexidartinib and emerging targeted therapies. By dynamically modulating ECM stiffness and mechanotransduction, we will improve the predictability of drug responses observed in vitro, making them more representative of patient outcomes. v) Pioneering the integration of magnetic actuation in tumor research: While magnetic technologies have been widely used in tissue engineering-including by the PI-their application in tumor modeling remains largely unexplored. This project represents a high-risk, high-gain approach, integrating magnetic actuation into a 3D tumor model to advance both fundamental cancer research and precision medicine.
By bridging mechanobiology, bioengineering, and oncology, MagTumor has the potential to fundamentally reshape TGCT research and therapeutic development. Success in this project could pave the way for next-generation tumor models, not only for TGCT but also for other mechanosensitive cancers, marking a major leap forward in preclinical research, therapeutic innovation, personalized medicine and precision oncology. |